Intratumoral Heterogeneity: More Than Just Mutations
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Most human tumors are composed of genetically and phenotypically heterogeneous cancer cell populations that poses a major challenge for the clinical management of cancer patients. Advances of single cell technologies have allowed the profiling of tumors at unprecedented depth, which in combination with newly-developed computational tools enable the dissection of tumor evolution with increasing precision. However, our understanding of mechanisms that regulate intratumoral heterogeneity and our ability to modulate it has been lagging behind. Recent data demonstrate that epigenetic regulators, including histone demethylases, may control the cell-to-cell variability of transcriptomes and chromatin profiles and they may modulate therapeutic responses via this function. Thus, the therapeutic targeting of epigenetic enzymes may be used to decrease intratumoral cellular heterogeneity and decrease treatment resistance when used in combination with other types of agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stochastic Gene Expression in a Single Cell
Elowitz, M. B., Levine, A. J., Siggia, E. D., & Swain, P. S. (2002) · Science · doi:10.1126/science.1070919 · Cited by 5,441 · cited 1×
“Such diversity may arise not only from genetic diversity but also from transcriptomic heterogeneity or noise in gene expression [57, 58] (Figure 2).”
BackgroundTransitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Bacterial Persistence as a Phenotypic Switch
Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., & Leibler, S. (2004) · Science · doi:10.1126/science.1099390 · Cited by 2,952
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136 · cited 1×
“An experimental mouse model of pancreatic cancer using tracking of lineage-labeled cells revealed that EMT can be detected in premalignant lesions and it may contribute to early dissemination even before tumor formation [42], further demonstrating the link between EMT and intratumor cellular heterogeneity and tumor pr…”
BackgroundChiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
kConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492 · cited 1×
“However, detailed molecular and functional analysis of normal breast tissue and breast tumors in BRCA1 germline mutation carriers in combination with engineered mouse models revealed that basal-like breast cancer could arise from luminal progenitors [35, 36].”
BackgroundPersistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243
Keren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.039 · Cited by 1,183 · cited 1×
“Cancer cell interaction with fibroblasts and the extracellular matrix (ECM) produced by them also trigger epigenetic alterations that could explain the distinct epigenetic profiles of cancer cells at the tumor-stroma interphase [28].”
BackgroundHata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.003 · Cited by 670
The Key Role of Epigenetics in Human Disease Prevention and Mitigation
Feinberg, A. P. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1402513 · Cited by 638
Tumour heterogeneity and metastasis at single-cell resolution
Lawson, D. A., Kessenbrock, K., Davis, R. T., Pervolarakis, N., & Werb, Z. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0236-7 · Cited by 606 · cited 1×
“Microenvironmental factors including hypoxia, tissue stiffness, and chronic inflammation can both directly and indirectly influence cancer cell epigenetic and phenotypic heterogeneity [21].”
BackgroundEpigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537 · cited 1×
“Recent work demonstrated that the combination of DNMTi and HDACi in vivo strongly induced the upregulation of CCL5, a chemokine involved in lymphocyte attraction, and this may contribute to the increased number of CD8+ T cells in tumors after treatment [85].”
BackgroundH3K4me3 breadth is linked to cell identity and transcriptional consistency
Benayoun, B. A., Pollina, E. A., Ucar, D., Mahmoudi, S., Karra, K., Wong, E. D., Devarajan, K., Daugherty, A. C., Kundaje, A. B., Mancini, E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.027 · Cited by 536
Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing
Casasent, A. K., Schalck, A., Gao, R., Sei, E., Long, A., Pangburn, W., Casasent, T., Meric-Bernstam, F., Edgerton, M. E., & Navin, N. E. (2018) · Cell · doi:10.1016/j.cell.2017.12.007 · Cited by 411
Deconstructing transcriptional heterogeneity in pluripotent stem cells
Kumar, R. M., Cahan, P., Shalek, A. K., Satija, R., Jay DaleyKeyser, A., Li, H., Zhang, J., Pardee, K., Gennert, D., Trombetta, J. J., et al. (2014) · Nature · doi:10.1038/nature13920 · Cited by 356
Guler, G. D., Tindell, C. A., Pitti, R., Wilson, C., Nichols, K., KaiWai Cheung, T., Kim, H.-J., Wongchenko, M., Yan, Y., Haley, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.002 · Cited by 277 · cited 1×
“Histone mass spectrometry analysis of EGFR-mutant NSCLC cells revealed that DTPs showed a global decrease in acetylated histone H3 (H3KAc) associated with active chromatin together with a global increase in H3K9me3 (histone H3 lysine 9 trimethyl) and H3K27me3 (histone H3 lysine 27 trimethyl) repressive marks ([53].”
BackgroundA problem of persistence: still more questions than answers?
Balaban, N. Q., Gerdes, K., Lewis, K., & McKinney, J. D. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3076 · Cited by 263
Hinohara, K., Wu, H.-J., Vigneau, S., McDonald, T. O., Igarashi, K. J., Yamamoto, K. N., Madsen, T., Fassl, A., Egri, S. B., Papanastasiou, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.014 · Cited by 255
Self-citationNotes on the role of dynamic DNA methylation in mammalian development
Bestor, T. H., Edwards, J. R., & Boulard, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415301111 · Cited by 238
Luo, W., Chang, R., Zhong, J., Pandey, A., & Semenza, G. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217394109 · Cited by 228 · cited 1×
“Hypoxia regulates the activity and protein levels of histone and DNA modifying enzymes including the G9a histone H3 lysine 9 (H3K9me) methyltransferase [22, 23], KDM4C and other histone demethylases [24, 25], and the TET family of DNA demethylases [26], which could explain hypoxia-induced epigenetic alterations within…”
BackgroundDifferentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Risom, T., Langer, E. M., Chapman, M. P., Rantala, J., Fields, A. J., Boniface, C., Alvarez, M. J., Kendsersky, N. D., Pelz, C. R., Johnson-Camacho, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05729-w · Cited by 174
Cited by
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
Self-citationExpression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?
Gires, O., Pan, M., Schinke, H., Canis, M., & Baeuerle, P. A. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09898-3 · Cited by 351
Cancer cell plasticity during tumor progression, metastasis and response to therapy
Pérez-González, A., Bévant, K., & Blanpain, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00595-y · Cited by 332
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
Wensink, G. E., Elias, S. G., Mullenders, J., Koopman, M., Boj, S. F., Kranenburg, O. W., & Roodhart, J. M. L. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00168-1 · Cited by 323
Carbone, A., Roulland, S., Gloghini, A., Younes, A., von Keudell, G., López-Guillermo, A., & Fitzgibbon, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0132-x · Cited by 278
Metadata
- Authors
- Hinohara, K., & Polyak, K.
- Venue
- Trends in Cell Biology
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 29
- Issue
- 7
- Pages
- 569-579
- ISSN
- 0962-8924 (ISSN-L)
- OpenAlex
- W2936025729
- Cited by
- 225
- References
- 24
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.